Arbutus Biopharma Corporation
ABUS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$69,920 | -$72,849 | -$69,456 | -$76,247 |
| Dep. & Amort. | $1,380 | $1,404 | $1,427 | $1,753 |
| Deferred Tax | $0 | $0 | $0 | -$8,177 |
| Stock-Based Comp. | $8,986 | $9,301 | $7,182 | $6,424 |
| Change in WC | -$2,829 | -$18,233 | $29,243 | $930 |
| Other Non-Cash | -$2,467 | -$5,559 | -$3,752 | $7,785 |
| Operating Cash Flow | -$64,850 | -$85,936 | -$35,356 | -$67,532 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$182 | -$1,008 | -$512 | -$809 |
| Net Acquisitions | $0 | $0 | $0 | $1,808 |
| Inv. Purchases | -$141,509 | -$80,509 | -$130,430 | -$82,219 |
| Inv. Sales/Matur. | $164,639 | $132,270 | $56,000 | $70,350 |
| Other Inv. Act. | $0 | $20 | $0 | -$1,808 |
| Investing Cash Flow | $22,948 | $50,773 | -$74,942 | -$12,678 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $44,123 | $29,852 | $20,324 | $134,665 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | -$12,139 |
| Other Fin. Act. | $7,873 | $795 | $11,490 | $14,710 |
| Financing Cash Flow | $51,996 | $30,647 | $31,814 | $137,236 |
| Forex Effect | -$49 | $25 | -$22 | $5 |
| Net Chg. in Cash | $10,045 | -$4,491 | -$78,506 | $57,031 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $26,285 | $30,776 | $109,282 | $52,251 |
| End Cash | $36,330 | $26,285 | $30,776 | $109,282 |
| Free Cash Flow | -$65,032 | -$86,944 | -$35,868 | -$68,341 |